313 related articles for article (PubMed ID: 9255257)
1. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
Dorfman DM; Shahsafaei A; Chan JK
Am J Surg Pathol; 1997 Aug; 21(8):936-40. PubMed ID: 9255257
[TBL] [Abstract][Full Text] [Related]
2. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
Tateyama H; Eimoto T; Tada T; Hattori H; Murase T; Takino H
Am J Clin Pathol; 1999 Feb; 111(2):235-40. PubMed ID: 9930146
[TBL] [Abstract][Full Text] [Related]
4. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
5. Intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) exhibits CD5 immunoreactivity: new evidence for thymic differentiation.
Dorfman DM; Shahsafaei A; Miyauchi A
Histopathology; 1998 Feb; 32(2):104-9. PubMed ID: 9543665
[TBL] [Abstract][Full Text] [Related]
6. CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms.
Kornstein MJ; Rosai J
Am J Clin Pathol; 1998 Jun; 109(6):722-6. PubMed ID: 9620029
[TBL] [Abstract][Full Text] [Related]
7. CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue.
Berezowski K; Grimes MM; Gal A; Kornstein MJ
Am J Clin Pathol; 1996 Oct; 106(4):483-6. PubMed ID: 8853036
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in thymic epithelial tumors with special reference to thymic carcinoma and atypical thymoma.
Hishima T; Fukayama M; Hayashi Y; Fujii T; Arai K; Shiozawa Y; Funata N; Koike M
Hum Pathol; 1998 Apr; 29(4):330-8. PubMed ID: 9563781
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
12. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric analysis of lymphoid cells in thymic epithelial neoplasms.
Nakajima J; Takamoto S; Oka T; Tanaka M; Takeuchi E; Murakawa T
Eur J Cardiothorac Surg; 2000 Sep; 18(3):287-92. PubMed ID: 10973537
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
[TBL] [Abstract][Full Text] [Related]
16. Type B3 thymic epithelial tumor in an adolescent detected by immunohistochemical staining for CD5, CD99, and KIT (CD117): a case report.
Yoshino N; Kubokura H; Yamauchi S; Oaki Y; Koizumi K; Shimizu K
Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):324-7. PubMed ID: 19901887
[TBL] [Abstract][Full Text] [Related]
17. PE-35-related antigen expression and CD1a-positive lymphocytes in thymoma subtypes based on Müller-Hermelink classification. An immunohistochemical study using catalyzed signal amplification.
Hattori H; Tateyama H; Tada T; Saito Y; Yamakawa Y; Eimoto T
Virchows Arch; 2000 Jan; 436(1):20-7. PubMed ID: 10664158
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical study of thymic epithelial tumors. I. Epithelial component.
Kodama T; Watanabe S; Sato Y; Shimosato Y; Miyazawa N
Am J Surg Pathol; 1986 Jan; 10(1):26-33. PubMed ID: 2420219
[TBL] [Abstract][Full Text] [Related]
19. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
20. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
